Compare American International Group Inc (AIG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Neurocrine Biosciences Inc — how do they compare? American International Group Inc trades at $79.98 (market cap $42.98B), while Neurocrine Biosciences Inc trades at $177.57 (market cap $17.84B). The key difference: American International Group Inc is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and American International Group Inc pays a 2.47% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AIG | NBIX | |
|---|---|---|
Market Cap | $42.98B | $17.84B |
Sector | Financials | Health |
52-Week High | $86.59 | $177.49 |
52-Week Low | $71.89 | $123.10 |
Enterprise Value | $50.68B | $16.93B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
